Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
High-Frequency Traders, a lot of brokers turn their trades over to HFTs and receive a kickback. Then the games start with the fractions of a penny.
Robinhood for example turns all their trades over to HFTs.
After 5 years Tinley is finally coming to market with cannabis-infused beverages. If you notice, everything is now in glass bottles as opposed to aluminum cans and plastic bottles, probably because, as we know cannabis bonds to the plastic lining of aluminum cans and plastic bottles. This gives a huge advantage to anyone licensing Lexaria technology because we don't have this problem with DehydraTECH.
https://thedeepdive.ca/tinley-beverage-announces-inaugural-product-shipment-from-long-beach-facility-issues-corporate-update/?fbclid=IwAR2BHv_-alROj9GnntObGlsRvrUhrRwDf848mQdIFc31VLz6Bnsv95evoho
Bunka controls and tracks Abundance88 through subliminal messages sent over the 5G network, that's a fact and Bill Gates will buy out Lexaria because DehydraTECH is the perfect vehicle to get a tracking chip into the body, much easier than with a vaccine which people are already on to.
You heard it here first!
Lexaria is not working on vapes. Just about anyone can liquefy nicotine and put it in a vape, but no one has been able to make a product that can be ingested orally until Lexaria. Nicotine aggravates the intestinal system and can make you violently ill, DehydraTECH avoids this and also speeds onset.
Stockwatch.com shows only 5000 volume and the bid and ask show halted. I e-mailed stockwatch and they said it was the data feed from CSE.
Apparently there's a problem with the data feed from the CSE so hard to tell what the trading really is in Canada.
Wait till China National Tobacco Corp. gets on board.
No mention of any cash payments to Lexy, that's a little disappointing but overall, fantastic news.
Thanks for tying that all together Abundance. I'm going to share your links.
Thanks, I was just going to bang off my own email, there must be some development in this regards.
What bothers me right now, is the fact that we haven't yet recieved IRB approval to conduct the trial as announced on March 19. Over 5 months and not a peep, it makes me suspect the whole thing has gone off the rails!
"Lexaria Bioscience Corp. is commencing a program, in collaboration with leading laboratories in Canada and the United States, to study the benefits of Lexaria's DehydraTech drug delivery platform for enhancing delivery and effectiveness of certain anti-retroviral drugs in the fight against coronavirus disease Covid-19."
"Lexaria intends to conduct the study at a leading Canadian University where a study design and plan has already been submitted for ethics board approval. Lexaria will provide further details upon successful conclusion of the review process as well as study outcomes when available."
Are you speculating about what might happen if the previous speculation about the sale of LN actually happens or do you have a source?
Remember how cannabis beverage makers are having a problem with the cannabis bonding to the lining or BPA of the containers? The problems with lined beverage containers go way beyond this.
https://www.ecowatch.com/bpa-plastic-premature-death-2647014739.html?rebelltitem=1#rebelltitem1
I hate it when someone shows up here and then wants us to do their due diligence for them.
You seem to forget the $1 million that Altria spent on research and development of oral nicotine products and the contributions of the NRC.
Waiting for something to happen with Lexaria is like watching DehydraTECH dry. LOL
When I say a lack of progress, I think of their plans for a clinical trial using DehydraTECH with anti-retroviral drugs. We've been waiting since March and we still haven't received approval to even begin. Stupid me, I thought it would all be fast-tracked, but maybe they did some more lab work and results were inconclusive and that's why they're not getting approval to start.
Lack of any progress, news.
Just getting their ducks in a row for uplisting me thinks.
No mention of Lexaria's technology in this article from two years ago, although they do mention lipids.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222489/
You're right that it wasn't awarded for CBD alone because you can't patent CBD. Their patents are for a method of reducing seizure frequency in patients and that method involves combining pure CBD with a delivery mechanism that greatly increases the bioavailability of CBD. This method reduces the need for Clobazam, a benzodiazepine (similar to valium).
Apparently GWPH has its own delivery system which is covered by the patents for Epidiolex. Epidiolex is simply purified CBD with this delivery system, CBD itself is not patentable.
whytestocks has awoken!
I've had this for a while I need .33 to break even.
Methinks big buyers are still waiting in the wings for more shares to come onto the market.
Looks like there is going to be heavy resistance at about the .60 cent level on LXX with the RSI becoming overbought.
Knock knocking at that 200 DMA. LXX .519 We posted a huge inverted bull hammer on the charts yesterday which is being confirmed today with a large white candlestick. Time to breakout out above 200 DMA!
We did 1,091,000 shares in Canada, best daily volume in over 2 years.
Anonymous doing the vast majority of buying and selling up North. Crazy.
Bought 427,153 Sold 349,131 Net 78,022
HMMJ-Horizons Marijuana Life Sciences
Institutional buying in Lxx for sure. Under the Anonymous banner so far: 382,000 bought 289,131 sold Net 93,269
It looks like LXX is going to for the highest daily volume in 2.5 years and the days not over!
652,000 now, but there's at least one aggressive seller of 220,000 he's been following the ask down trying to unload.
Yeah, it got a bit ahead of itself, up too far too fast.
https://www.stockwatch.com/News/Item?bid=Z-C:*MKTPOT-2935804&symbol=*MKTPOT®ion=C
Cannabis Summary for July 17, 2020
2020-07-17 20:24 ET - Market Summary
by Stockwatch Business Reporter
The S&P/TSX Cannabis Index lost 1.2 points to 152.96 Friday, ending the week up 6.74 points. The Canadian Securities Exchange Composite Index, meanwhile, slipped 1.88 points to 431.04 today, finishing the week up 11.68 points. In company news, Chris Bunka's Lexaria Bioscience Corp. (LXX) gained two cents to 42 cents on 103,300 shares again today after rising six cents yesterday. The modest gains, which brought the stock out of 52-week-low territory, came on news that Lexaria completed phase 1 of its nicotine delivery technology research and development (R&D) program.
The program is researching Lexaria's DehydraTech technology. It is being conducted jointly with Altria Ventures Inc., a subsidiary of tobacco giant Altria Group Inc. and an investor in Lexaria subsidiary Lexaria Nicotine. Lexaria is researching to see if its oral nicotine technology reduces the health risks associated with traditional tobacco use (through smoking or chewing tobacco). Phase 1 of testing was more about safety than effectiveness. The tests concluded that the technology demonstrated "acceptable chemical and microbiological stability" and there were no adverse effects in a seven-day test with rats.
Altria Group has a licensing agreement that would allow it to use Lexaria's DehydraTech technology in its tobacco products. Lexaria will receive royalty payments if Altria decides to use the technology. The tobacco company has invested $1-million (U.S.) in Lexaria Nicotine so far. That can increase to up to $12-million (U.S.) if Altria decides to exercise outstanding warrants. The conclusion of phase 1 R&D gives Altria 90 days to decide if it wants to acquire Lexaria shares under the first warrant tranche. If it does, it would allow Altria to retain its exclusive rights to use Lexaria's DehydraTech as a nicotine delivery method in the United States. Whether Altria exercises the warrants or not, the tobacco company will retain its current ownership and its non-exclusive licence to use the technology internationally. Eventually, Altria could have the option to acquire all of Lexaria Nicotine "commensurate with then-current fair market value." If Altria were to acquire Lexaria Nicotine, the royalty payments would stop.
Shareholders should temper their excitement for now: Lexaria makes clear that Altria has not yet even confirmed that it will use the technology commercially. In the meantime, Lexaria is showing the technology to other tobacco, nicotine and pharmaceutical companies. Lexaria says it is in discussions with two other companies that are "each one of the world's 10 largest tobacco firms."
While its nicotine division seems to have many promotional possibilities, the company has similar oral delivery technology on the cannabis side. Lexaria reached a deal at the start of 2020 to provide its technology to Cannadips CBD, a smokeless CBD dip brand. Cannadips' product is similar to a Snus pouch, where the consumer tucks the pouch under his lip. Lexaria's technology is supposed to make the pouches more effective (higher CBD absorption) and quicker to take effect.
The above all sounds promising, but the company has yet to produce any sales of substance. In an optimistic note at the start of the year, Lexaria chief executive officer Chris Bunka projected the company's revenue to "more than double" in 2020. Instead, the growth has been slow. In fiscal Q1, which ended Nov. 30, the company had $62,000 (U.S.) in revenue. Lexaria followed that up with revenue of $107,000 (U.S.) in fiscal Q2 but that pulled back to $81,000 (U.S.) in fiscal Q3.
While the market responded favourably to the R&D program, before that move Lexaria was near its 52-week low of 31 cents. Today's closing price of 42 cents is an improvement, but still nowhere near the company's 52-week high of $1.30. Mr. Bunka holds 13.4 million shares in Lexaria, which would be worth about $5.6-million today.
1933 Industries Inc. (TGIF) slipped half a cent to 6.5 cents on 3.11 million shares after arranging a $5-million financing. The financing will be for up to 66.66 million units at 7.5 cents (the company has 285 million shares outstanding). Each unit will come with a share and a half warrant, where each full warrant will be exercisable at 12.5 cents for 24 months.
If the company finds enough investors to raise the $5-million, it would replenish 1933's bank account nicely. As of April 30, the cannabis producer had cash of $4.8-million (and no debt). It had gone through $4.3-million of cash in the quarter ending April 30 though, so that balance would not likely have lasted long.
That being said, the company says it has cut costs significantly. The cost-cutting has come with declining sales though. 1933 had fiscal Q3 sales of $2.6-million, down from $3.1-million in fiscal Q2.
On Wednesday evening, Dan Bilzerian's Ignite International Brands Ltd. (BILZ: $0.92) quietly released its first quarter results for 2020. Yesterday, the stock rose 10 cents from 85 to 95 cents, and then gave three cents back today.
For the uninitiated, the CEO of the company, Dan Bilzerian, is somewhat of an Internet celebrity. With 32 million followers on Instagram, he calls himself a former professional poker player but he became famous for posting photos and videos with scantily clad models, private jets and luxurious yachts. He seems to be more of a hands-off CEO as he rarely if ever provides commentary in the company's news releases. In any case, what he does indisputably provide the company with is brand awareness. He constantly posts photos of models dawning Ignite-branded bikinis to his Instagram account (presumably these women are paid - part of the company's exorbitant marketing budget).
The stock rose despite Ignite only recording revenue of $1.6-million in Q1 2020, down sharply from $2.6-million in Q4 2019. On the bright side, Ignite only lost $9-million in the first quarter, an improvement over its $33.5-million Q4 loss (although the Q4 figure included impairment charges for $21.8-million).
Ignite's losses have largely been the result of spending on marketing and promotion. The company has dialed it back to some degree, but its Q1 marketing spending of $2.1-million still exceeded its revenue in the quarter. That was at least down from a marketing expense of $3.4-million in Q4 2019 and a ridiculous $6.6-million in Q3 2019.
Investors may have held out hope that Mr. Bilzerian's Instagram account would be a useful marketing tool. That seemed like a reasonable theory, but it has not played out. Most of Ignite's shareholders would be underwater by now. Today's 92-cent closing price is down from a 52-week high of $3 but better than its COVID-19 low of 61 cents. Given all of the facts mentioned, the company may need to find a new promotional angle if it is to keep investors on board.
© 2020 Canjex Publishing Ltd. All rights reserved.
Thanks, Nostra that's great exposure.
Whytestocks has awoken!
We're back to dreaming of a Fortune 500 White Knight.